Safety and Immunogenicity of Intradermal, and Low-Dose Subcutaneous vs Subcutaneous Administration of Menomune- A/C/Y/W-135.

Trial Profile

Safety and Immunogenicity of Intradermal, and Low-Dose Subcutaneous vs Subcutaneous Administration of Menomune- A/C/Y/W-135.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 polysaccharide; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 01 May 2009 Primary endpoints added as reported by ClinicalTrials.gov.
    • 26 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top